Tumor MK2 transcript levels are associated with improved response to chemotherapy and patient survival in non-small cell lung cancer

Karthik Suresh, Othello Del Rosario, Medha Kallem, Gayatri Singh, Anika Shah, Linda Zheng, Xin Yun, Nicolas M. Philip, Nirupama Putcha, Marni B. McClure, Haiyang Jiang, Franco D’alessio, Meera Srivastava, Alakesh Bera, Larissa A. Shimoda, Michael Merchant, Madhavi J. Rane, Carolyn E. Machamer, Jason Mock, Robert HaganAbigail L. Koch, Naresh M. Punjabi, Todd M. Kolb, Mahendra Damarla

Research output: Contribution to journalArticlepeer-review

Abstract

Non-small cell lung cancers (NSCLCs) demonstrate intrinsic resistance to cell death, even after chemotherapy. Previous work suggested defective nuclear translocation of active caspase-3 in observed resistance to cell death. We have identified mitogen-activated protein kinase-activated protein kinase 2 (MK2; encoded by the gene MAPKAPK2) is required for caspase-3 nuclear translocation in the execution of apoptosis in endothelial cells. The objective was to determine MK2 expression in NSCLCs and the association between MK2 and clinical outcomes in patients with NSCLC. Clinical and MK2 mRNA data were extracted from two demographically distinct NSCLC clinical cohorts, North American (The Cancer Genome Atlas, TCGA) and East Asian (EA). Tumor responses following first round of chemotherapy were dichotomized as clinical response (complete response, partial response, and stable disease) or progression of disease. Multivariable survival analyses were performed using Cox proportional hazard ratios and Kaplan-Meier curves. NSCLC exhibited lower MK2 expression than SCLC cell lines. In patients, lower tumor MK2 transcript levels were observed in those presenting with late-stage NSCLC. Higher MK2 expression was associated with clinical response following initial chemotherapy and independently associated with improved 2-yr survival in two distinct cohorts, 0.52 (0.28–0.98) and 0.1 (0.01–0.81), TCGA and EA, respectively, even after adjusting for common oncogenic driver mutations. Survival benefit of higher MK2 expression was unique to lung adenocarcinoma when comparing across various cancers. This study implicates MK2 in apoptosis resistance in NSCLC and suggests prognostic value of MK2 transcript levels in patients with lung adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)168-178
Number of pages11
JournalPhysiological Genomics
Volume55
Issue number4
DOIs
StatePublished - Apr 2023

Keywords

  • MAPKAPK2
  • TCGA
  • caspase-3
  • chemotherapy
  • non-small cell lung cancer
  • survival

ASJC Scopus subject areas

  • Genetics
  • Physiology

Fingerprint

Dive into the research topics of 'Tumor MK2 transcript levels are associated with improved response to chemotherapy and patient survival in non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this